Tango Therapeutics (NASDAQ:TNGX – Free Report) had its price target reduced by Wedbush from $45.00 to $40.00 in a research report sent to investors on Tuesday,Benzinga reports. Wedbush currently has an outperform rating on the stock.
Other equities analysts also recently issued research reports about the stock. Mizuho boosted their target price on shares of Tango Therapeutics from $36.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, July 17th. HC Wainwright cut their target price on shares of Tango Therapeutics from $68.00 to $67.00 and set a “buy” rating for the company in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tango Therapeutics in a report on Wednesday, November 4th. Guggenheim lifted their price target on shares of Tango Therapeutics from $32.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 12th. Finally, Stifel Nicolaus set a $55.00 price target on shares of Tango Therapeutics in a research note on Friday, October 23rd. Thirteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $45.54.
Read Our Latest Research Report on Tango Therapeutics
Tango Therapeutics Price Performance
NASDAQ TNGX opened at $24.85 on Tuesday. The stock’s 50 day moving average is $23.47 and its 200 day moving average is $22.72. Tango Therapeutics has a 12 month low of $7.49 and a 12 month high of $34.39.
Tango Therapeutics (NASDAQ:TNGX – Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.04). As a group, equities research analysts expect that Tango Therapeutics will post -1.46 earnings per share for the current fiscal year.
Insider Activity
In other news, insider Adam Crystal sold 27,000 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $24.47, for a total transaction of $660,690.00. Following the transaction, the insider owned 115,743 shares of the company’s stock, valued at approximately $2,832,231.21. This represents a 18.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Jessica Newcomb sold 8,200 shares of the company’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $24.22, for a total value of $198,604.00. Following the completion of the transaction, the insider directly owned 59,121 shares in the company, valued at $1,431,910.62. This trade represents a 12.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 47,231 shares of company stock worth $1,129,029 over the last quarter. 6.50% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Tango Therapeutics
Several large investors have recently modified their holdings of the business. First Trust Advisors LP boosted its position in Tango Therapeutics by 20.6% during the 3rd quarter. First Trust Advisors LP now owns 614,160 shares of the company’s stock valued at $15,323,000 after acquiring an additional 104,851 shares in the last quarter. Bessemer Group Inc. raised its position in shares of Tango Therapeutics by 11.2% in the 3rd quarter. Bessemer Group Inc. now owns 393,824 shares of the company’s stock worth $9,826,000 after acquiring an additional 39,618 shares in the last quarter. ACT Capital Partners L.P. bought a new position in shares of Tango Therapeutics in the 3rd quarter worth $150,000. Fisher Asset Management LLC lifted its stake in shares of Tango Therapeutics by 84.8% during the 3rd quarter. Fisher Asset Management LLC now owns 1,068,505 shares of the company’s stock worth $26,659,000 after purchasing an additional 490,347 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Tango Therapeutics by 4.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 13,734 shares of the company’s stock worth $336,000 after purchasing an additional 534 shares during the last quarter. Institutional investors own 78.99% of the company’s stock.
Trending Headlines about Tango Therapeutics
Here are a few of the latest headlines about TNGX:
- Positive Sentiment: Canaccord Genuity maintained its Buy rating on TNGX, while JPMorgan also issued a positive outlook. Separate coverage linked an analyst upgrade to a recent share-price rally. Canaccord Genuity rating JPMorgan outlook Analyst upgrade and rally
- Positive Sentiment: TNGX shares recently moved above their 50-day moving average, a potentially supportive technical signal, despite the earnings miss. Shares move above 50-day average
- Negative Sentiment: HC Wainwright lowered its 2026 and 2027 EPS forecasts, including its FY2027 estimate from a loss of $1.54 to $1.75 per share. It nevertheless kept its Buy rating and $67 target. The revised forecasts point to greater expected losses and could weigh on sentiment. HC Wainwright forecast changes
About Tango Therapeutics
Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.
Featured Articles
- Five stocks we like better than Tango Therapeutics
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Tango Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tango Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
